Science Explorer Back to mapMap

Most cited papers from Alnylam Pharmaceuticals (United States)

What are the most cited papers from Alnylam Pharmaceuticals (United States)?

The most cited paper from Alnylam Pharmaceuticals (United States) is "Silencing of microRNAs in vivo with ‘antagomirs’" (Jan Krützfeldt, Nikolaus Rajewsky, Ravi S Braich et al., 2005), with 3,987 citations. Next come "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" (3,046) and "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts" (2,368).

Showing 50 of 60 papers. Every paper with more than 364 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Silencing of microRNAs in vivo with ‘antagomirs’ Jan Krützfeldt, Nikolaus Rajewsky, Ravi S Braich et al. · Nature 30 Oct 2005 3,987
2 Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis David H Adams et al. · New England Journal of Medicine Open access 4 Jul 2018 3,046
3 MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts Thomas Thum et al. · Nature 30 Nov 2008 2,368
4 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs Jürgen Soutschek et al. · Nature Nov 2004 2,191
5 Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters Markus Feuerer, Laura Herrero, Daniela Cipolletta et al. · Nature Medicine Open access 26 Jul 2009 2,160
6 Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter Joshua M. Baughman, Fabiana Perocchi, Hany S. Girgis et al. · Nature Open access 17 Jun 2011 1,960
7 Rational design of cationic lipids for siRNA delivery Sean C. Semple et al. · Nature Biotechnology 17 Jan 2010 1,819
8 Plasma proteomic associations with genetics and health in the UK Biobank Benjamin B. Sun et al. · Nature Open access 4 Oct 2023 1,716
9 Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape Jérôme Gilleron, William Querbes, Anja Zeigerer et al. · Nature Biotechnology 23 Jun 2013 1,660
10 The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs Akin Akinc, Martin A. Maier, Muthiah A. Manoharan et al. · Nature Nanotechnology Open access Dec 2019 1,651
11 RNAi-mediated gene silencing in non-human primates Tracy S. Zimmermann et al. · Nature 26 Mar 2006 1,355
12 Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** Muthusamy Jayaraman, Steven M. Ansell, Barbara L. Mui et al. · Angewandte Chemie International Edition Open access 10 Jul 2012 1,268
13 Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms Akin Akinc et al. · Molecular Therapy Open access 11 May 2010 1,263
14 A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Akin Akinc et al. · Nature Biotechnology Open access 27 Apr 2008 1,238
15 Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 Veit Hornung, Margit Guenthner‐Biller, Carole Bourquin et al. · Nature Medicine Open access 20 Feb 2005 1,235
16 Interfering with disease: a progress report on siRNA-based therapeutics Antonin de Fougerolles, Hans-Peter Vornlocher, John M. Maraganore et al. · Nature Reviews Drug Discovery ReviewOpen access Jun 2007 1,204
17 From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus Kiran Musunuru et al. · Nature Open access Aug 2010 1,204
18 Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery Hyukjin Lee, Abigail K. R. Lytton‐Jean, Yi Chen et al. · Nature Nanotechnology Open access Jun 2012 1,180
19 miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection Qi-Jing Li, Jacqueline Chau, Peter Ebert et al. · Cell Open access 23 Mar 2007 1,160
20 Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing Jayaprakash K. Nair et al. · Journal of the American Chemical Society Dec 2014 1,126
21 RNAi therapeutics: a potential new class of pharmaceutical drugs David A. Bumcrot, Muthiah A. Manoharan, Victor Koteliansky et al. · Nature Chemical Biology Open access 15 Nov 2006 1,091
22 MicroRNAs 103 and 107 regulate insulin sensitivity Mirko Trajkovski, Jean Hausser, Jürgen Soutschek et al. · Nature Open access Jun 2011 995
23 Mechanisms and optimization of in vivo delivery of lipophilic siRNAs Christian Wolfrum, Shuanping Shi, K. Narayanannair Jayaprakash et al. · Nature Biotechnology 16 Sep 2007 982
24 Lipid-like materials for low-dose, in vivo gene silencing Kevin T. Love, Kerry P. Mahon, Christopher G. Levins et al. · Proceedings of the National Academy of Sciences Open access 11 Jan 2010 982
25 Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis Teresa Coelho et al. · New England Journal of Medicine Open access 28 Aug 2013 981
26 Chemistry, structure and function of approved oligonucleotide therapeutics Martin Egli, Muthiah A. Manoharan · Nucleic Acids Research Open access 7 Mar 2023 851
27 Therapeutic siRNA silencing in inflammatory monocytes in mice Florian Leuschner et al. · Nature Biotechnology Open access 9 Oct 2011 847
28 A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 Kevin J. Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine Open access 13 Nov 2016 773
29 First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement Josep M. Tabernero et al. · Cancer Discovery 28 Jan 2013 709
30 Origins of tumor-associated macrophages and neutrophils Virna Cortez‐Retamozo, Martin Etzrodt, Andita Newton et al. · Proceedings of the National Academy of Sciences Open access 30 Jan 2012 702
31 Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown Anders Wittrup, Angela Ai, Xing Liu et al. · Nature Biotechnology Open access 20 Jul 2015 693
32 Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Maria D. Frank-Kamenetsky et al. · Proceedings of the National Academy of Sciences Open access 11 Aug 2008 647
33 Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics Martin A. Maier et al. · Molecular Therapy Open access 25 Jun 2013 640
34 Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity Kathryn A. Whitehead, J. Robert Dorkin, Arturo J. Vegas et al. · Nature Communications Open access 27 Jun 2014 635
35 Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria Manisha Balwani et al. · New England Journal of Medicine Open access 10 Jun 2020 617
36 In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight James E. Dahlman et al. · Nature Nanotechnology Open access 11 May 2014 590
37 Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Kevin J. Fitzgerald, Maria D. Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet Open access 3 Oct 2013 580
38 A viral microRNA functions as an orthologue of cellular miR-155 Eva Gottwein, Neelanjan Mukherjee, Christoph Sachse et al. · Nature Open access Dec 2007 568
39 Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma Maria-del-Mar Inda, Rudy Bonavia, Akitake Mukasa et al. · Genes & Development Open access 15 Aug 2010 549
40 Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1 Sander F. Garrelfs et al. · New England Journal of Medicine Open access 31 Mar 2021 520
41 Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles Barbara L. Mui, Ying K. Tam, Muthusamy Jayaraman et al. · Molecular Therapy — Nucleic Acids Open access 2013 504
42 MICU1 Controls Both the Threshold and Cooperative Activation of the Mitochondrial Ca2+ Uniporter György Csordás, Tünde Golenár, Erin L. Seifert et al. · Cell Metabolism Open access Jun 2013 500
43 Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates Yizhou Dong et al. · Proceedings of the National Academy of Sciences Open access 10 Feb 2014 492
44 Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing Jens Harborth, Sayda M. Elbashir, Kim Vandenburgh et al. · Antisense and Nucleic Acid Drug Development Apr 2003 476
45 MICU2, a Paralog of MICU1, Resides within the Mitochondrial Uniporter Complex to Regulate Calcium Handling Molly Plovanich, Roman L. Bogorad, Yasemin Sancak et al. · PLoS ONE Open access 7 Feb 2013 476
46 Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis Scott David Solomon, David H Adams, Arnt V. Kristen et al. · Circulation 17 Jan 2019 465
47 Specificity, duplex degradation and subcellular localization of antagomirs Jan Krützfeldt, Satoru Kuwajima, Ravi S Braich et al. · Nucleic Acids Research Open access 16 Apr 2007 459
48 A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus John P. DeVincenzo, Rob Lambkin‐Williams, Tom M. A. Wilkinson et al. · Proceedings of the National Academy of Sciences Open access 26 Apr 2010 442
49 Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank Joseph D. Szustakowski et al. · Nature Genetics 111 authors 28 Jun 2021 439
50 Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation Chai-Wan Kim, Carol Addy, Jun Kusunoki et al. · Cell Metabolism Open access Aug 2017 425

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.